GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.

Alters, Susan E; McLaughlin, Bryant; Spink, Benjamin; Lachinyan, Tigran; Wang, Chia-wei; Podust, Vladimir; Schellenberger, Volker; Stemmer, Willem P C

Alters, Susan E; McLaughlin, Bryant; Spink, Benjamin; Lachinyan, Tigran; Wang, Chia-wei; Podust, Vladimir; Schellenberger, Volker; Stemmer, Willem P C.

Affiliation

Alters SE; Amunix Inc., Mountain View, California, United States of America. salters@amunix.com

PLoS One ; 7(11): e50630, 2012.

Article in En | MEDLINE | ID: mdl-23189208

Subject(s)

Crohn Disease/drug therapy; Glucagon-Like Peptide 2/therapeutic use; Animals; Crohn Disease/blood; Crohn Disease/chemically induced; Disease Models, Animal; Female; Glucagon-Like Peptide 2/chemistry; Glucagon-Like Peptide 2/pharmacokinetics; Humans; Indomethacin; Intestine, Small/drug effects; Intestine, Small/pathology; Macaca fascicularis; Male; Mice; Rats; Recombinant Fusion Proteins/chemistry; Recombinant Fusion Proteins/pharmacokinetics; Recombinant Fusion Proteins/therapeutic use

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Crohn Disease / Glucagon-Like Peptide 2 Type of study: Prognostic_studies Limits: Animals / Female / Humans / Male Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2012 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google